Bharat Biotech's TB vaccine MTBVAC begins clinical trials in India

COVID-19: Zydus Cadila gets DCGI nod for phase-III clinical trials

<p>Ahmedabad based Zydus Cadila Pharmaceuticals has announced that the company has received an approval from the Drugs Controller General of India -DCGI to begin the phase-III clinical trials with its biological therapy Pegylated Interferon alpha-2b (PegiHep) in Covid-19 patients. PegiHep is an approved drug and is being re-purposed for the treatment of Covid-19. According to […]</p>